Microtubule Assembly Inhibitors (Griseofulvin)


Article Author:
Jazmine Olson


Article Editor:
Neil Shah


Editors In Chief:
Jessica Snowden
Asif Noor
H Davies


Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes


Updated:
12/25/2018 12:02:27 PM

Indications

Griseofulvin is FDA approved for and also the drug of choice in tinea capitis, although itraconazole and terbinafine have come to be more common choices than griseofulvin for tinea capitis in adults.[1] It is the most commonly prescribed medication for tinea capitis treatment in children due to its cost-effectiveness and easy accessibility.[2] Among antifungal therapies for tinea capitis, griseofulvin and terbinafine were found to have the highest clinical and complete cure rates.[2] In the same study, griseofulvin more effectively treated Microsporum than Trichophyton. However, it is important to note that in the United States the most common causative agent of tinea capitis is Trichophyton tonsurans. The efficacy of griseofulvin is improved when used in combination with selenium sulfide shampoo.

Griseofulvin is also indicated in onychomycosis, although it has largely been replaced by newer antifungals such as terbinafine, itraconazole, and fluconazole.[3] The cause of the majority of onychomycosis is by T. rubrum and T. interdigitale.[4] There is high-quality evidence that compared to placebo it is an effective treatment for onychomycosis with regards to both clinical and mycologic cure. Treatment is partly dependent on the rate of nail growth. Toenails grow at a slower rate than fingernails, sometimes taking as long as 12-18 months to grow in its entirety, and have a decreased rate of treatment success.[5][6] Nail debridement may assist in the success of treatment.[4]

Additionally, griseofulvin is used to treat superficial fungal infections that are resistant to treatment with topical antifungal medications, with the exception being tinea capitis for which it is first-line as mentioned above. It is usually the first-line choice for this purpose in children. It can also be used for severe and diffuse superficial fungal infections. Examples of such infections include tinea manuum, tinea unguium, tinea corporis, and tinea cruris.

Mechanism of Action

Griseofulvin is a microtubule assembly inhibitor. It interacts with microtubules to affect the formation of the mitotic spindle. This interference ultimately inhibits mitosis in dermatophytes. With this mechanism, griseofulvin serves as a fungistatic agent against Trichophyton, Microsporum, and Epidermophyton species.[2] It is noteworthy that it is not effective in treating dimorphic fungi, yeast (Malassezia, Candida), or chromomycosis. Griseofulvin is quickly eliminated from the body and thus must be taken over an extended period to have efficacy.[2]

Administration

Griseofulvin is an oral medication. It comes in microsize (250 and 500 mg tablets) and ultramicrosize (125 and 250 mg tablets) forms. Ultramicrosize tablets are absorbed better than microsize. Griseofulvin is poorly water soluble. Griseofulvin is best taken with a high-fat meal to increase absorption from the GI tract.[2] The duration of therapy is long (e.g., 6-12 weeks for tinea capitis) which may lead to noncompliance. It is also available in a liquid suspension formulation. In tinea capitis, recommended doses are 20-25 mg/kg/day for microsize and 10-15 mg/kg/day for ultramicrosize. Each of these medications should be taken daily for 6 or more weeks and continued until the patient is clinically asymptomatic.

Adverse Effects

Overall, griseofulvin has few adverse effects. It most commonly causes gastrointestinal issues of nausea, vomiting, and diarrhea as well as headache and allergic reactions.[3] Other adverse effects include photosensitivity, fixed drug eruption, petechiae, pruritus, and urticaria. It may cause a worsening of lupus or porphyria.

Griseofulvin is an inducer of cytochrome P-450 and thus interacts with medications that metabolize via the P-450 system. One such drug is warfarin. When taken with griseofulvin, warfarin's anticoagulation effect decreases.[7] Additionally, griseofulvin increases the effects of alcohol and may cause a disulfiram-like reaction.[8]

In a study involving 295 children, 79 (or 26.8%) experienced mild to moderate adverse effects with the most common being gastrointestinal. These included elevated triglycerides (1/79), anemia (2/79), SGOT (serum glutamic-oxaloacetic transaminase; 1/79), rash (1/79), abdominal pain (10/79), diarrhea (7/79), dyspepsia (3/79), fever (1/79), headache (12/79), nausea (9/79), weight gain (3/79), vomiting (12/79), and other unspecified events (17/79).[2] All of these adverse effects were transient, and none were considered severe.

Contraindications

Griseofulvin is a pregnancy category C medication. It should not be prescribed to pregnant women due to its reports of causing fetal abnormalities in rats and dogs. Cases of conjoined twins have also been reported in women taking griseofulvin during their first trimester of pregnancy. Patients should wait at least a month after completion of treatment with griseofulvin before becoming pregnant.[9] Do not use griseofulvin in a person who has a hypersensitivity to any portion of the medication. It is also contraindicated in patients with hepatic failure and those with a diagnosis of porphyria cutanea tarda.[10]

Monitoring

Whether there is a benefit to monitoring alanine aminotransferase (ALT), aspartate aminotransferase (AST), and complete blood count (CBC) with differential is a concern for some providers prescribing griseofulvin. A large retrospective study performed in adults and children taking griseofulvin or terbinafine for dermatophyte infections provided clarity on this question. There was a low rate of laboratory test result abnormalities. Most of these were low grade and did not require discontinuation of the medication or repeat laboratory evaluation. Elevations in ALT, elevations in AST, anemia, lymphopenia, and neutropenia were all infrequent and comparable to baseline rates of abnormalities. With these results, it appears unnecessary in both adults and children to perform interval laboratory tests in patients taking griseofulvin for dermatophyte infections.[11]

Enhancing Healthcare Team Outcomes

When considering superficial fungal infections, it is essential to make an accurate diagnosis to prevent treatment failure. However, it is also important to treat the infection in a timely manner to prevent the spread of infection and its sequelae. In particular, tinea capitis can lead to permanent baldness. This can have a serious psychosocial effect on children. For this reason, it is important to diagnose and treat tinea capitis early in its course. Providers should be aware that current doses of griseofulvin are effective and safe to use for tinea capitis in children (I).

It merits mention that griseofulvin is not effective in treating dimorphic fungi, yeast (Malassezia, Candida), or chromomycosis. It has been incorrectly prescribed to treat diseases caused by these organisms, such as candidal intertrigo, for which it is ineffective. This causes frustration and disappointment for patients as well as a delay in resolution of infection and increased risk of spread to others. Providers should be aware that griseofulvin is only effective against Trichophyton, Microsporum, and Epidermophyton species and not against the organisms noted above (I).

Finally, as mentioned above under "Monitoring," it appears unnecessary to perform interval laboratory test monitoring, including AST, ALT, and CBC, in patients taking griseofulvin. Providers are often hesitant to provide these oral medications to patients with superficial dermatophyte infections. Because laboratory tests are costly to the healthcare system and both inconvenient and stressful for patients, providers should be aware that interval laboratory test monitoring has not been shown to be of benefit in patients taking griseofulvin for dermatophyte infections (III).


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Microtubule Assembly Inhibitors (Griseofulvin) - Questions

Take a quiz of the questions on this article.

Take Quiz
Which antifungal agent has no activity for oral infections?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following investigations are recommended before administering griseofulvin?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is incorrect about treating tinea capitis with oral griseofulvin?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Griseofulvin is FDA approved to treat which of the following infections?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 10-year-old male presents with scalp irritation and hair loss. Fungal culture reveals infection with Microsporum species. He is prescribed oral griseofulvin for six weeks. Which of the following laboratory tests should be measured upon initiation of the medication and at intervals during treatment?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Microtubule Assembly Inhibitors (Griseofulvin) - References

References

Tinea capitis in children: a systematic review of management., Gupta AK,Mays RR,Versteeg SG,Piraccini BM,Shear NH,Piguet V,Tosti A,Friedlander SF,, Journal of the European Academy of Dermatology and Venereology : JEADV, 2018 May 24     [PubMed]
Tinea Capitis in Children and Trichoscopic Criteria., Elghblawi E,, International journal of trichology, 2017 Apr-Jun     [PubMed]
Oral antifungal medication for toenail onychomycosis., Kreijkamp-Kaspers S,Hawke K,Guo L,Kerin G,Bell-Syer SE,Magin P,Bell-Syer SV,van Driel ML,, The Cochrane database of systematic reviews, 2017 Jul 14     [PubMed]
Blank H, The actions and interactions of drugs: the therapeutic significance of enzyme induction. Transactions of the St. John's Hospital Dermatological Society. 1967     [PubMed]
Smith EB, The treatment of dermatophytosis: safety considerations. Journal of the American Academy of Dermatology. 2000 Nov     [PubMed]
Spiro JM,Demis DJ, The effects of griseofulvin on porphyria cutanea tarda. The Journal of investigative dermatology. 1968 Mar     [PubMed]
Gupta AK,Foley KA,Versteeg SG, New Antifungal Agents and New Formulations Against Dermatophytes. Mycopathologia. 2017 Feb     [PubMed]
Gupta AK,Cooper EA, Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008 Nov-Dec     [PubMed]
Gupta AK,Daigle D,Foley KA, Topical therapy for toenail onychomycosis: an evidence-based review. American journal of clinical dermatology. 2014 Dec     [PubMed]
Katz HI, Systemic antifungal agents used to treat onychomycosis. Journal of the American Academy of Dermatology. 1998 May     [PubMed]
Stolmeier DA,Stratman HB,McIntee TJ,Stratman EJ, Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections. JAMA dermatology. 2018 Oct 17     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pediatric-Infectious Diseases. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pediatric-Infectious Diseases, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pediatric-Infectious Diseases, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pediatric-Infectious Diseases. When it is time for the Pediatric-Infectious Diseases board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pediatric-Infectious Diseases.